SM Investments not endorsing Hyflux’s current rescue deal
The investor said on Thursday the ‘allocation set out in the schemes of arrangement proposed by Hyflux is not agreed. Therefore, the schemes do not satisfy the conditions of the restructuring agreement.’
Salim-Medco (SM) Investments has stated that it does not endorse on the current rescue deal that Hyflux plans to put to a creditors’ vote in the upcoming scheme meeting on April 5.
The Indonesian investor group that offered a S$530 million lifeline in exchange for a 60% stake in Hyflux once all its debts are cleared said on Thursday the ‘allocation set out in the schemes of arrangement proposed by Hyflux is not agreed. Therefore, the schemes do not satisfy the conditions of the restructuring agreement.’
SM Investments stated that it recently became aware of new material information on Hyflux that significantly increases the working capital requirements of the group.
The current allocation from Hyflux has not been agreed upon by the investor, and does not satisfy the conditions of the existing deal, it claimed.
‘In light of the new material information disclosed to SM Investments, it has been reviewing the allocation of the investment for the working capital requirements of the Hyflux group. This will in turn affect the amount available for settlement to creditors.’
Had this material information been disclosed earlier, it would have been taken into consideration in the allocation previously discussed with creditor groups, the investor said.
‘Under the restructuring agreement (signed on October 18 last year), the allocation of the investment between working capital and the amount available for settlement to creditors is to be agreed between Hyflux and SM Investments,’ it added.
Hyflux notes some disagreements with investor, but will proceed on scheme meetings
The statement from SM Investments is in contrast with water treatment firm Hyflux’s comments earlier this week and Hyflux has disputed the reasoning from its white knight investor to excuse itself from the restructuring agreement deal agreed in October.
Hyflux did state that it has several disagreements with the investor, but it stressed that it has the intention to proceed with the scheme meetings scheduled next month.
Hyflux had said that the S$271 million it plans to carve out from SM Investment's potential cash injection to settle its debts with creditors was agreed upon by SM Investments prior to the publication of the schemes on February 16 and called the recent claims from the investor a ‘belated assertion’.
Hyflux added that it has tried but has been unable to meaningfully engage with the investor. It will, pursuant to contractual obligations, use reasonable endeavours to ensure the necessary conditions under the restructuring agreement are satisfied in order for the investment to proceed.
Location change to accommodate a larger attendance for upcoming scheme meeting
To cater to a larger number of attendees, Hyflux will be changing the location for its upcoming scheme meeting on April 5 to The Star Performing Arts Centre, The Star Theatre at 12 noon for banks, noteholders, trade creditors and contingent creditors, and at 7 pm for holders of perpetual capital securities and preference shares.
The attendees will be putting to a vote on the firm’s restructuring plan during the meeting.
The firm has previously reiterated its intention to proceed with the scheme meetings scheduled on April 5 and April 8, as well as the extraordinary general meeting to approve the terms of the investment on April 15.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
See opportunity on a stock?
Don’t miss your chance. Try a risk-free trade in your demo account, and find out whether your hunch could have paid off.
- Log in to your demo
- Try a risk-free trade
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance. Upgrade to a live account to take advantage.
- Trade a wide range of popular global stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform, when it matters
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Live prices on most popular markets
You might be interested in…
Find out what charges your trades could incur with our transparent fee structure.
Discover why so many clients choose us, and what makes us a world-leading provider of spread betting and CFDs.
Stay on top of upcoming market-moving events with our customisable economic calendar.